Effects of combined therapy with glipizide and Aralia root bark extract on glycemic control and lipid profiles in patients with type 2 diabetes mellitus

Journal of the Science of Food and Agriculture

Volumn 95, Issue 4, 2015, Pages 739-744

  Liu, Xiao Hong ^a   Li, Xing Min ^b   Han, Cheng Cheng ^a   Fang, Xiang Feng ^b   Ma, Le ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Tirain Technology Co Ltd   (China)

Author keywords

Antioxidants; Aralia; Glycemic control; Lipid status; Type 2 diabetes mellitus

Indexed keywords

ARALIA;

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; GLIPIZIDE; PLANT EXTRACT;

ADVERSE EFFECTS; ARALIA; BARK; BLOOD; CHEMISTRY; CHINA; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIAS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIAL;

ANTIOXIDANTS; ARALIA; CHINA; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GLIPIZIDE; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INTENTION TO TREAT ANALYSIS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; PATIENT DROPOUTS; PLANT BARK; PLANT EXTRACTS;

EID: 84922371583     PISSN: 00225142     EISSN: 10970010     Source Type: Journal    
DOI: 10.1002/jsfa.6829     Document Type: Article

References (26)

1. Saad A, Dalla Man C, Nandy DK, Levine JA, Bharucha AE, Rizza RA et al., Diurnal pattern to insulin secretion and insulin action in healthy individuals. Diabetes 61:2691-2700 (2012).
2. Wild S, Roglic G, Green A, Sicree R and King H, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053 (2004).
3. American Diabetes Association, Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36:1033-1046 (2013).
4. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J et al., Prevalence of diabetes among men and women in China. N Engl J Med 362:1090-1101 (2010).
5. Mitka M, More patients get good diabetes control, but only a minority meet all goals. JAMA 309:1335-1336 (2013).
6. Fu AZ, Qiu Y, Davies MJ and Engel SS, Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus. Diabetes Ther 3:12 (2012).
7. Fulgêncio Cunha AA, Bosco AA, Veloso CA, Volpe CM, Chaves MM and Nogueira-Machado JA, Suppressive effect of aqueous humor from person with Type 2 diabetes with or without retinopathy on reactive oxygen species generation. Diabetes Res Clin Pract 100:69-73 (2013).
8. Bi L, Tian X, Dou F, Hong L, Tang H and Wang S, New antioxidant and antiglycation active triterpenoid saponins from the root bark of Aralia taibaiensis. Fitoterapia 83:234-240 (2012).
9. Castellano JM, Guinda A, Delgado T, Rada M and Cayuela JA, Biochemical basis of the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes. Diabetes 62:1791-1799 (2013).
10. Motomura K, Fujiwara Y, Kiyota N, Tsurushima K, Takeya M, Nohara T, Nagai R and Ikeda T, Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products. J Agric Food Chem 57:7666-7672 (2009).
11. Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K et al., Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis 223:197-203 (2012).
12. Victor VM, Rocha M, Herance R and Hernandez-Mijares A, Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr Pharm Des 17:3947-3958 (2011).
13. Kaneto H and Matsuoka TA, Involvement of oxidative stress in suppression of insulin biosynthesis under diabetic conditions. Int J Mol Sci 13:13680-13690 (2012).
14. Giacco F and Brownlee M, Oxidative stress and diabetic complications. Circ Res 107:1058-1070 (2010).
15. Kaneto H, Katakami N, Matsuhisa M and Matsuoka TA, Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm 2010:453892 (2010).
16. Wang X, Liu R, Zhang W, Zhang X, Liao N, Wang Z et al., Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects. Mol Cell Endocrinol 376:70-80 (2013).
17. Xi M, Hai C, Tang H, Chen M, Fang K and Liang X, Antioxidant and antiglycation properties of total saponins extracted from traditional Chinese medicine used to treat diabetes mellitus. Phytother Res 22:228-237 (2008).
18. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB et al., Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327-336 (2011).
19. Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ et al., Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 33:469-476 (2011).
20. Bonora E, Kiechl S, Mayr A, Zoppini G, Targher G, Bonadonna RC et al., High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care 34:1038-1040 (2011).
21. Jenkins DJ, Kendall CW, McKeown-Eyssen G, Josse RG, Silverberg J, Booth GL et al., Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA 300:2742-2753 (2008).
22. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R et al., Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753-759 (2007).
23. Gujral UP, Pradeepa R, Weber MB, Narayan KM and Mohan V, Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann NY Acad Sci 1281:51-63 (2013).
24. Fukushima M, Suzuki H and Seino Y, Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 66:S37-43 (2004).
25. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA et al., Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 299:1678-1689 (2008).
26. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A et al., Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299:1561-1573 (2008).